MediGene

Industry · 12 registered clinical trials.

Status	Trial	Phase	Started
Completed	Study Evaluating the Pharmacokinetic Profile of Novel Formulations of RHUDEX® Formulation Finding	Phase 1	2011-12-01
Completed	Systemic Exposure of Catechins From Veregen 15% Ointment in Patients With External Anogenital Warts and From O Anogenital Warts	Phase 1	2011-12-01
Completed	Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage Genital Warts, Perianal Warts	Phase 4	2010-01-01
Terminated	Study Evaluating the Pharmacokinetic Profile of RhuDex® in a Tablet Formulation Pharmacokinetics	Phase 1	2008-05-01
Completed	A Trial Evaluating the Pharmacokinetics and Mode of Action of EndoTAG®-1 in Tumor Patients With Hepatic Metast Liver Cancer, Neoplasm Metastasis	Phase 2	2007-11-01
Completed	Phase-I Study Evaluating the Pharmacokinetic Profile of RhuDex® Pharmacokinetics	Phase 1	2007-09-01
Completed	EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients Breast Neoplasms	Phase 2	2007-01-01
Completed	EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Adenocarcinoma, Metastasis, Pancreas Neoplasms	Phase 2	2005-09-01
Completed	G207 Followed by Radiation Therapy in Malignant Glioma Malignant Glioma	Phase 1	2005-05-01
Completed	Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver Colorectal Cancer, Liver Neoplasms	Phase 1 / Phase 2	2004-07-01
Completed	Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts Condylomata Acuminata	Phase 3	2003-07-01
Completed	Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer Glioma, Astrocytoma, Glioblastoma	Phase 1 / Phase 2	2001-12-01